Medicine and Dentistry
Adverse Event
12%
Aflibercept
69%
Age Related Macular Degeneration
47%
Angiography
7%
Arm
8%
Best Corrected Visual Acuity
47%
Biological Marker
6%
Bleeding
6%
Brolucizumab
14%
Central Retinal Vein Occlusion
15%
Choroidal Neovascularization
16%
Clinical Trial
9%
Diabetic Macular Edema
65%
Diabetic Retinopathy
34%
Disease Activity
7%
Diseases
9%
Drug Megadose
7%
Eye Disease
7%
Faricimab
10%
Fluocinolone Acetonide
7%
Fluorescein Angiography
19%
Fundus Fluorescein Angiography
7%
Geographic Atrophy
10%
Intravitreal Administration
8%
Laser Coagulation
21%
Macular Degeneration
7%
Macular Edema
20%
Macular Hole
10%
Optical Coherence Tomography
32%
Pegcetacoplan
7%
Post-Hoc Analysis
5%
Randomized Clinical Trial
10%
Ranibizumab
55%
Retina Vein Occlusion
10%
Retinal Detachment
5%
Retinopathy
7%
Retreatment
10%
Spectral Domain Optical Coherence Tomography
15%
Subgroup Analysis
7%
Subretinal Fluid
9%
Telangiectasia
5%
Triamcinolone Acetonide
7%
Vasculotropin
32%
Visual Acuity
38%
Visual Impairment
5%
Wet Macular Degeneration
69%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
19%
Aflibercept
100%
Age Related Macular Degeneration
42%
Angiopoietin 2
8%
Antiplatelet
5%
Bevacizumab
7%
Brolucizumab
15%
Central Retina Vein Occlusion
12%
Clinical Trial
15%
Dexamethasone
7%
Diabetic Macular Edema
91%
Diabetic Retinopathy
38%
Disease Activity
7%
Diseases
8%
Endothelial Cell Growth Factor
13%
Faricimab
21%
Fluocinolone Acetonide
18%
Fluorescein
13%
Implant
10%
Intravitreal Administration
6%
Macular Edema
5%
Nesvacumab
7%
Photodynamic Therapy
7%
Proliferative Diabetic Retinopathy
11%
Randomized Clinical Trial
21%
Randomized Controlled Trial
5%
Ranibizumab
89%
Retina Detachment
8%
Retina Disease
5%
Retina Vein Occlusion
10%
Subretinal Neovascularization
17%
Vasculotropin
35%
Verteporfin
10%
Wet Macular Degeneration
99%
Keyphrases
2-year Outcome
7%
Aflibercept
33%
Age-related Macular Degeneration
5%
Anti-VEGF Therapy
7%
Best-corrected Visual Acuity
19%
Brolucizumab
10%
Central Subfield Thickness
5%
Clinical Comparison
7%
Diabetic Macular Edema
37%
ETDRS
5%
Faricimab
7%
Intravitreal
9%
Intravitreal Aflibercept
23%
Intravitreal Aflibercept Injection
29%
Ischemic Index
5%
Lucentis
5%
Macular Edema
14%
Myopic Choroidal Neovascularization (mCNV)
6%
Navigated Laser
10%
Neovascular Age-related Macular Degeneration (nAMD)
35%
Neovascular AMD
6%
Nesvacumab
7%
Nicolaus Copernicus
7%
Proliferative Diabetic Retinopathy
5%
Randomized Trial
7%
Ranibizumab
23%
Retinal Thickness
7%
Retinal Vascular Bed Area
7%
Retinal Vein Occlusion
12%
Sham
8%
Subretinal Fluid
6%
Treat-and-extend
14%
Ultra-widefield Fluorescein Angiography
7%
Vascular Endothelial Growth Factor
5%
Visudyne
5%